NO20065578L - Substituerte metylaryl eller heteroarylamidforbindelser - Google Patents

Substituerte metylaryl eller heteroarylamidforbindelser

Info

Publication number
NO20065578L
NO20065578L NO20065578A NO20065578A NO20065578L NO 20065578 L NO20065578 L NO 20065578L NO 20065578 A NO20065578 A NO 20065578A NO 20065578 A NO20065578 A NO 20065578A NO 20065578 L NO20065578 L NO 20065578L
Authority
NO
Norway
Prior art keywords
compounds
provides
methylaryl
substituted
heteroarylamide
Prior art date
Application number
NO20065578A
Other languages
English (en)
Norwegian (no)
Inventor
Tatsuya Yamagishi
Kazunari Nakao
Yoshiyuki Okumura
Hiroki Koike
Yukari Matsumoto
Kana Kon-I
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065578(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO20065578L publication Critical patent/NO20065578L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20065578A 2004-05-04 2006-12-04 Substituerte metylaryl eller heteroarylamidforbindelser NO20065578L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04
PCT/IB2005/001134 WO2005105732A1 (fr) 2004-05-04 2005-04-22 Composes methylaryl- ou heteroarylamides substitues

Publications (1)

Publication Number Publication Date
NO20065578L true NO20065578L (no) 2007-01-12

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065578A NO20065578L (no) 2004-05-04 2006-12-04 Substituerte metylaryl eller heteroarylamidforbindelser

Country Status (29)

Country Link
US (2) US7534914B2 (fr)
EP (1) EP1756042B8 (fr)
JP (1) JP4054368B2 (fr)
KR (1) KR20070006891A (fr)
CN (1) CN1950333A (fr)
AP (1) AP2006003785A0 (fr)
AR (1) AR048642A1 (fr)
AU (1) AU2005238291A1 (fr)
BR (1) BRPI0510666A (fr)
CA (1) CA2565813C (fr)
CR (1) CR8730A (fr)
DO (1) DOP2005000071A (fr)
EA (1) EA200601847A1 (fr)
EC (1) ECSP066968A (fr)
ES (1) ES2461265T3 (fr)
GT (1) GT200500101A (fr)
IL (1) IL178676A0 (fr)
MA (1) MA28571B1 (fr)
MX (1) MXPA06011555A (fr)
NL (1) NL1028947C2 (fr)
NO (1) NO20065578L (fr)
PA (1) PA8631201A1 (fr)
PE (1) PE20060306A1 (fr)
SV (1) SV2005002102A (fr)
TN (1) TNSN06358A1 (fr)
TW (1) TW200536541A (fr)
UY (1) UY28877A1 (fr)
WO (1) WO2005105732A1 (fr)
ZA (1) ZA200608393B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7446220B2 (en) * 2005-09-19 2008-11-04 Teva Pharmaceutical Industries Ltd. Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
DE502006003145D1 (de) 2005-12-28 2009-04-23 Basf Se Verfahren zur herstellung von (r)- und (s)-4-(1-aminomethyl)benzoesäuremethylester-sulfat aus racemischem 4-(1-amin0ethyl)benzoesäuremethylester
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
WO2008017164A1 (fr) * 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Dérivés de thiophènecarboxamide en tant que ligands du récepteur ep4
EA015931B1 (ru) 2006-12-15 2011-12-30 Глэксо Груп Лимитед Бензамидные производные как агонисты ер-рецепторов
US20110028463A1 (en) * 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
GB0721611D0 (en) * 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
KR101612971B1 (ko) * 2008-05-14 2016-04-15 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
EP2297090A1 (fr) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Synthèse enzymatique stéréosélective de l ester (s) ou (r)-isobutylglutarique
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
MX369117B (es) 2009-04-22 2019-10-28 Askat Inc Antagonistas del receptor ep4 para el tratamiento de cancer.
RU2571816C2 (ru) 2010-02-22 2015-12-20 Раквалиа Фарма Инк. Применение антагонистов рецептора ep4 в лечении il-23-опосредуемых заболеваний
LT2619182T (lt) * 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
US8828987B2 (en) 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
BR112014000087B1 (pt) 2011-07-04 2021-08-17 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas do receptor ep4
WO2013032975A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Polymère cristallin liquide thermotrope à viscosité à faible cisaillement améliorée
WO2013032967A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Pièces coulées au moule formées à partir d'un polymère cristallin liquide
JP2014525498A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
US8778221B2 (en) 2011-08-29 2014-07-15 Ticona Llc Aromatic amide compound
WO2013032974A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Polymérisation à l'état solide d'un polymère cristallin liquide
CN103764793B (zh) 2011-08-29 2016-09-14 提克纳有限责任公司 高流动液晶聚合物组合物
WO2013032977A1 (fr) 2011-08-29 2013-03-07 Ticona Llc Composition de polymère à cristaux liquides résistante à la chaleur ayant une faible température de fusion
CN103764741B (zh) 2011-08-29 2015-09-23 提克纳有限责任公司 低熔体粘度液晶聚合物的熔融聚合
US8852730B2 (en) 2011-08-29 2014-10-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (fr) 2013-02-22 2014-08-28 Ticona Llc Composition de polymères haute performance présentant des propriétés d'écoulement améliorées
CN105163761B (zh) * 2013-03-19 2018-12-21 株式会社AskAt Ep4受体拮抗剂在软骨疾病的治疗中的用途
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
US9206300B2 (en) 2013-06-07 2015-12-08 Ticona Llc High strength thermotropic liquid crystalline polymer
SG11201510121RA (en) 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
PT3083562T (pt) 2013-12-17 2017-12-13 Lilly Co Eli Derivados de aminas cíclicas de fenoxietilo e a sua atividade como moduladores de recetores ep4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
EP3625224B1 (fr) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd Dérivés d'indole n-substitués
LT3625228T (lt) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd Pirimidino dariniai, kaip pge2 receptoriaus moduliatoriai
CR20190559A (es) 2017-05-18 2020-02-10 Idorsia Pharmaceuticals Ltd Derivados de fenilo como moduladores del receptor de pge2
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
AU2020360970A1 (en) * 2019-10-02 2022-05-26 Domain Therapeutics Prostaglandin E2 (PGE2) EP4 receptor antagonists
CN114075140A (zh) * 2020-08-18 2022-02-22 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途
WO2022102731A1 (fr) 2020-11-13 2022-05-19 小野薬品工業株式会社 Traitement du cancer par utilisation combinée d'un antagoniste d'ep4 et d'un inhibiteur de point de contrôle immunitaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
ID22781A (id) 1997-04-04 1999-12-09 Pfizer Prod Inc Turunan-turunan nikotinamida
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
EP1185508A2 (fr) 1999-05-24 2002-03-13 Cor Therapeutics, Inc. Inhibiteurs du facteur xa
US6924391B2 (en) * 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
EP1229034B1 (fr) 2001-01-31 2005-04-13 Pfizer Products Inc. Derivés du nicotinamide et leur mimetiques actifs comme ihibiteurs de PDE4 isozymes
CN1551866A (zh) 2001-08-09 2004-12-01 СҰҩƷ��ҵ��ʽ���� 羧酸衍生物化合物及包含这些化合物为活性成分的药物
WO2003030937A1 (fr) 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedes contre des maladies liees au stress comprenant des antagonistes de recepteurs mithochondriaux de la benzodiazepine

Also Published As

Publication number Publication date
US20090163558A1 (en) 2009-06-25
PA8631201A1 (es) 2005-11-25
NL1028947C2 (nl) 2006-04-10
GT200500101A (es) 2005-12-12
EP1756042B8 (fr) 2014-06-04
JP2007536366A (ja) 2007-12-13
UY28877A1 (es) 2005-12-30
SV2005002102A (es) 2005-12-13
CA2565813A1 (fr) 2005-11-10
KR20070006891A (ko) 2007-01-11
PE20060306A1 (es) 2006-04-14
BRPI0510666A (pt) 2007-12-04
ZA200608393B (en) 2008-05-28
TNSN06358A1 (fr) 2008-02-22
MXPA06011555A (es) 2006-12-15
US7534914B2 (en) 2009-05-19
AR048642A1 (es) 2006-05-10
DOP2005000071A (es) 2005-11-30
WO2005105732A8 (fr) 2007-04-19
ES2461265T3 (es) 2014-05-19
AU2005238291A1 (en) 2005-11-10
EP1756042B1 (fr) 2014-02-12
CR8730A (es) 2006-11-30
US20050267170A1 (en) 2005-12-01
WO2005105732A1 (fr) 2005-11-10
AP2006003785A0 (en) 2006-10-31
CN1950333A (zh) 2007-04-18
ECSP066968A (es) 2006-12-29
EA200601847A1 (ru) 2007-04-27
JP4054368B2 (ja) 2008-02-27
NL1028947A1 (nl) 2005-11-07
US8084476B2 (en) 2011-12-27
EP1756042A1 (fr) 2007-02-28
MA28571B1 (fr) 2007-05-02
CA2565813C (fr) 2010-10-26
IL178676A0 (en) 2007-02-11
TW200536541A (en) 2005-11-16

Similar Documents

Publication Publication Date Title
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
NO20065573L (no) Orto-substituerte aryl eller heteroarylamidforbindelser
NO20061251L (no) Fenyl eller pyridylamidforbindelser som prostaglanding-E2-antagonister
DK1618092T3 (da) Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
NO20055590L (no) Kinaseinhiberende fosfonatanaloger
ATE503746T1 (de) Neue imidazolidinderivate
NO20064032L (no) DPP-IV inhibitorer
NO20075809L (no) DNA-PK inhibitorer
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
MX2009004343A (es) Compuestos organicos.
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
DK1831239T5 (da) Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-gamma-lacton og nøgle-mellemprodukter til denne fremgangsmåde
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
GB2470170A (en) Dithienothiophene derivatives
MY161992A (en) Novel tetrahydroisoquinoline derivative
DK2000473T3 (da) Trehalose-forbindelse og lægemiddel omfattende forbindelsen
NO20071107L (no) 1,1,2,2-tetra(hetero)aryletaner eller 1,1,2-tri(hetero)aryl-2-heterosyklyletaner som kaliumkanalinhibitorer
MY142362A (en) Pharmaceutical composition for promoting angiogenesis
MY154026A (en) Anti-bacterial pyrocatechols and related methods
CY1112166T1 (el) Παραγωγο αζολιου χρησιμο ως αντιμυκητιακοι παραγοντες με μειωμενη αλληλεπιδραση με μεταβολικα κυτοχρωματα

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application